WO1993010153A1 - Produit bactericide, composition pharmaceutique le contenant et additif alimentaire - Google Patents
Produit bactericide, composition pharmaceutique le contenant et additif alimentaire Download PDFInfo
- Publication number
- WO1993010153A1 WO1993010153A1 PCT/FR1992/001063 FR9201063W WO9310153A1 WO 1993010153 A1 WO1993010153 A1 WO 1993010153A1 FR 9201063 W FR9201063 W FR 9201063W WO 9310153 A1 WO9310153 A1 WO 9310153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bactericidal
- product according
- bactericidal product
- product
- hemoglobin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to new bactericidal substances having a broad spectrum of activity.
- Antiseptics are chemical agents that stop and destroy microorganisms. Mention may be made, for example, of chlorhexidine, halogens, heavy metal salts, quaternary ammoniums, salicyic acid and its derivatives.
- Antibiotics are originally defined as chemicals produced by microorganisms that have the power to inhibit or destroy bacteria and other microorganisms, in dilute solution. A large number of these molecules are currently prepared by hemisynthesis or chemical synthesis.
- These molecules can have a bacteriostatic or bactericidal action.
- beta-lactams penicillins and cephalosporins
- aminoglycosides aminoglycosides
- cyclins aminoglycosides
- phenicolics macrohdes
- polymyxins polymyxins and quinolones.
- Another group of antibacterial products is sulfa drugs.
- One of the advantages of the product according to the present invention is to present an interesting activity on bacteria involved in disorders of the digestive system, in particular Clostridium. Indeed, it has been discovered that porphyritic derivatives have bactericidal activity.
- the present invention relates to a bactericidal product, characterized in that it comprises a porphine nucleus.
- the invention relates to porphyrin derivatives, for their application as therapeutically active substances, in particular as bactericidal products.
- bactericidal products which are particularly suitable according to the invention are the products comprising at least one molecule chosen from hemin and hematine; the invention also relates to a bactericidal product which comprises at least part of the heme group, or at least one molecule derived from chlorophyllins, which are salts of the various chlorophylls.
- the bactericidal product according to the invention can be prepared by synthesis, at least for its porphyritic part; this has advantages both for security reasons and for specific action.
- the bactericidal product can be prepared by incubating a substrate containing hemoglobin with an enzymatic mixture containing at least one protease (then recovery of the solution of the product obtained).
- the bactericidal product can be obtained from various substrates containing hemoglobin, in particular from whole blood, red blood cells, erythrocyte content or purified hemoglobin.
- An enzyme mixture containing at least one protease, in particular trypsin, is made to act on this substrate; however, better results are obtained by combining trypsin with other enzymes, such as those found in pancreatic juice or in feces supernatants from axenic animals.
- the bactericidal product can also be obtained by incubation of a substrate containing hemoglobin with proteinase K.
- the hydrolysis is then preferably carried out at a temperature of the order of 50 ° C.
- the conditions for incubation will depend on the activity of the enzyme mixture and the origin of the substrate, but digestion is preferably carried out at 37 ° C for about 24 hours, but it is possible to use lower temperatures up to at 20 ° C, and durations of the order of 1 hour to 72 hours.
- the product according to the present invention can be prepared in particular by the following process:
- a mammalian whole blood sample is centrifuged, and the pellet containing the erythrocytes is collected, b) after washing (for example with an isotonic buffer solution), the pellet is placed in the presence of distilled water to cause hemolysis of the erythrocytes,
- step c) the supernatant obtained at the end of step c) is incubated with pancreatic juice
- Blood can come from different mammals. It is collected on an anticoagulant such as heparin.
- the erythrocytes are isolated, for example by centrifugation at 2000 rpm, 10 min at + 4 ° C, then washed in the same volume of buffer, preferably PBS buffer; they are then hemolyzed by adding the same volume of distilled water, and the cell debris is separated from the erythrocyte content by centrifugation, for example at 13,000 rpm, 10 min at + 4 ° C.
- the extract obtained can be stored at +4 ° C or frozen at -20 ° C, if it is not immediately subjected to the action of enzymes.
- Incubation in the presence of the enzyme mixture is more particularly carried out at 37 ° C. for 24 hours, aerobically, after dilution of the substrate in the enzyme preparation.
- the bactericidal product can be obtained by incubating purified human or animal hemoglobin with pancreatic juice. This product can be sterilized by filtration.
- pancreatic juice pancreatic pork juice, diluted to 2%, will preferably be used.
- the bactericidal activity of the product is carried by the porphyritic fraction, which is insoluble in water.
- Products solubied in water therefore comprise the porphine nucleus optionally substituted and / or complexed by a metal, and associated with a residue of 3 to 10 amino acids, more particularly amino acids originating from the chains of globin.
- Such a compound has good bactericidal activity, favored by a solubility allowing good distribution in biological fluids.
- this product shows that the activity of the product is maintained in the intestinal contents. It is therefore a product which is not absorbed and remains in the lumen of the digestive tract; furthermore, this product is not degraded by digestive enzymes.
- the bactericidal product can contain a greater number of amino acids, which increases its solubility and allows its possible passage through the digestive barrier to have systemic activity.
- the active molecules have as a common structure the porphyrinic group and different by the residues of amino acids maintained associated with the porphyry nucleus.
- the bactericidal product according to the invention is a product having a substantial part of a peptide nature which can come from globin.
- the product obtained is certainly made up of a mixture of molecules which differ in their number of amino acids.
- the bactericidal product according to the invention is active on strict anaerobic gram bacteria, in particular on bacteria of the genus Clostridium, such as Clostridium perfringens, Clostridium butyricum, and sporules isolated from the human flora. It is not active on several Clostridium difficile strains. It is active on other strains of the dominant flora of adult humans, such as bifides, peptostreptococci, and Eubacterium.
- This product is therefore particularly interesting since it is a product of natural origin, active on germs responsible for particularly dangerous infections; for example Clostridium butyricum is involved in ulcerative necrotizing enterocoiitis of the newborn. This product therefore gives birth to a new generation of inhibitory substances, lyophilizable, sterilizable by filtration.
- This purified product can be used in particular as a food additive, for example to avoid the disorders observed during the weaning of the piglet.
- the bactericidal products according to the invention can also be used as preservatives.
- the present invention therefore relates to medicinal compositions comprising, as active principle, a product according to the present invention with an excipient compatible with a therapeutic application, in particular by the oral route.
- They may especially be compositions such as tablets, tablets, powder or other form which can be administered orally.
- the present invention also relates to tablets intended for food, in particular animal feed, containing its concentrates of the product according to the invention intended to be added to food proper, thirst in drinking water or else premixtures of animal feed containing the product according to the invention.
- the freshly prepared or stored blood substrates are diluted 1 / 10th and 1 / 20th in the enzyme preparations, they are incubated for 24 hours at 37 ° C.
- pancreatic enzymes Incubation of whole human blood, a pellet of washed red blood cells or the soluble fraction of hemolyzed red blood cells with pancreatic enzymes generates bactericidal activity in vitro.
- the production of inhibitory substances is the result of an enzymatic process: the blood substrates and enzymes alone have no effect.
- the substrates are not the constituents of serum and plasma.
- the enzymatic activity is exerted on the red blood cells, not on the wall, but on the erythrocyte content.
- the bactericidal effect is less strong with whole blood; this is probably linked to the presence of tryptic inhibitors.
- the bactericidal activity is stronger after the action of enzyme mixtures such as those present in the faeces of axenic animals or in pancreatic juice than with trypsin alone.
- Heglobins preferably purified (H) of human (H1) or animal (H2) origin are treated with any type of protease, not necessarily digestive.
- H1 or H2 origin are treated with any type of protease, not necessarily digestive.
- purified proteinase K which hydrolyzes proteins, glycoproteins, peptides and esters of amino acids.
- H1 purified human hemoglobin (Sigma H7379). H1 is diluted and used at the same concentration as that of the blood of an adult man. 12.5 to 15 g of hemoglobin are diluted in 100 ml of 0.01 M PBS.
- H2 crude or purified bovine hemoglobin (Sigma H2625- H2500). H2 is prepared as H1 but diluted 10 times, ie 1.2 to 1.5 g / 100ml of PBS. b) Enzymatic preparation
- Proteinase K is used at several concentrations, preferably at the final concentration of 0.1 mg / ml of hemoglobin to be hydrolyzed.
- the hydrolysis is preferably carried out at 50 ° C with slow stirring.
- the hydrolysis time is variable from 1 hour to 24 hours.
- the hydrolysates obtained after 2 hours of incubation generate good antibiotic activity.
- the hydrolysate results obtained show that the erythrocyte content or the purified hemoglobin treated with proteinase K at 0.1 mg / ml generates an inhibiting substance on BFR effective up to 1 / 128.
- the amount of bactericidal substance produced depends on the hemoglobin concentration to be hydrolyzed.
- the hydrolyzate of the erythrocyte content by the pancreatic juice produces a more diffusible and therefore more soluble substance.
- the inhibitory effect obtained either with a porphine (hematoporphyrin) or with substitution derivatives combined with iron (hemin, hematine) or with magnesium (chlorophylline) confirms that the porphyry nuclei are involved in bactericidal activity.
- the nature of the metal complex alone (Fe or Mg) or chemically combined (FeCl, FeOH) is not. decisive.
- the nuclei are insoluble in water but they can be chemically dissolved (case of chlorophyllin) or obtained more or less soluble (case of hydrolysates) depending on the degree of denaturation of the associated globin, depending on the efficiency of the protease used ( pancreatic juice and proteinase K for example).
- Bacillus subtilis the BFR strain isolated from a canned food which has the distinction of being easy to handle: mesophilic strain, strict aerobic, capable of initiating an abundant population in 6 hours of culture at laboratory temperature .
- mesophilic strain strict aerobic, capable of initiating an abundant population in 6 hours of culture at laboratory temperature .
- This strain does not spore in the above culture medium.
- This strain is very sensitive to different types of antibiotics and will be used to test the various hydrolysates, the controls on the one hand, and, on the other hand to research and control the fate of the active fractions in the purification treatments.
- the hydrolyzate ES used pure and diluted up to 1/32, prevents bacterial multiplication and kills bacteria in the inoculum.
- the 1/32 dilution represents the minimum inhibitory concentration from which the bactericidal effect appears.
- Bactericidal test techniques on bacterial strains The optional anaerobic strains are tested like the control strain Bacilius FR.
- EOS very sensitive to oxygen
- Freter an anaerobic chamber
- - the anaerobic strains less sensitive to oxygen are seeded outside in the agar mass. They are incubated for 48 hours at 37 ° C in an anaerobic jar (Gaspack system).
- the antibiotic in the raw hydrolyzate is not absorbed. It passes through the digestive tract of the axenic mouse and is found active on BFR in all the contents and faeces 3 h 30 after the first ingestion.
- the appearance of a small area of antibiosis in IG3 could correspond to the inhibitory effect of digestive substances secreted in the small intestine and reabsorbed in the cecum.
- the purified fraction HPLC.C 18 studied in Sephadex LH20 filtration gel is eluted in a single active fraction absorbing at 214 and 380 nm at a corresponding molecular weight between 600 and 1000 daitons.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93900252A EP0613484A1 (fr) | 1991-11-15 | 1992-11-16 | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire |
JP5509034A JPH07501328A (ja) | 1991-11-15 | 1992-11-16 | 殺菌性生成物、これを含む医薬組成物および食品添加物 |
CA002123587A CA2123587A1 (fr) | 1991-11-15 | 1992-11-16 | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR91/14090 | 1991-11-15 | ||
FR9114090A FR2683724A1 (fr) | 1991-11-15 | 1991-11-15 | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993010153A1 true WO1993010153A1 (fr) | 1993-05-27 |
Family
ID=9418976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1992/001063 WO1993010153A1 (fr) | 1991-11-15 | 1992-11-16 | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0613484A1 (fr) |
JP (1) | JPH07501328A (fr) |
AU (1) | AU3163093A (fr) |
CA (1) | CA2123587A1 (fr) |
FR (1) | FR2683724A1 (fr) |
WO (1) | WO1993010153A1 (fr) |
ZA (1) | ZA928679B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033463A2 (fr) * | 1994-06-02 | 1995-12-14 | Bar-Ilan University | Compositions antibiotiques synergique contenant une porphyrine et un antibiotique |
EP0824213A2 (fr) * | 1996-08-15 | 1998-02-18 | Tsukasa Matsumoto | Méthode pour le fractionnement des globules rouges et matériaux antibactériens ou inhibiteurs de prolifération bactérienne ainsi produit |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101547691A (zh) * | 2006-06-29 | 2009-09-30 | 悠哈味觉糖有限公司 | 动脉硬化抑制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0061556A1 (fr) * | 1979-11-16 | 1982-10-06 | AB Pripps Bryggerier | Préparation d'acides aminés enrichie en fer hématinique et procédé pour la confection de préparations d'acides aminés enrichies en fer hématinique à partir d'hémoprotéines |
FR2628118A1 (fr) * | 1988-03-07 | 1989-09-08 | Centre Nat Rech Scient | Fractions peptidiques issues d'hemolysats de cruor, leur obtention et leurs applications |
EP0438750A2 (fr) * | 1990-01-23 | 1991-07-31 | Morinaga Milk Industry Co., Ltd. | Utilisation d'un hydrolysat de lactoferrine comme agent antibactérien |
-
1991
- 1991-11-15 FR FR9114090A patent/FR2683724A1/fr active Pending
-
1992
- 1992-11-11 ZA ZA928679A patent/ZA928679B/xx unknown
- 1992-11-16 JP JP5509034A patent/JPH07501328A/ja active Pending
- 1992-11-16 EP EP93900252A patent/EP0613484A1/fr not_active Withdrawn
- 1992-11-16 WO PCT/FR1992/001063 patent/WO1993010153A1/fr not_active Application Discontinuation
- 1992-11-16 CA CA002123587A patent/CA2123587A1/fr not_active Abandoned
- 1992-11-16 AU AU31630/93A patent/AU3163093A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0061556A1 (fr) * | 1979-11-16 | 1982-10-06 | AB Pripps Bryggerier | Préparation d'acides aminés enrichie en fer hématinique et procédé pour la confection de préparations d'acides aminés enrichies en fer hématinique à partir d'hémoprotéines |
FR2628118A1 (fr) * | 1988-03-07 | 1989-09-08 | Centre Nat Rech Scient | Fractions peptidiques issues d'hemolysats de cruor, leur obtention et leurs applications |
EP0438750A2 (fr) * | 1990-01-23 | 1991-07-31 | Morinaga Milk Industry Co., Ltd. | Utilisation d'un hydrolysat de lactoferrine comme agent antibactérien |
Non-Patent Citations (4)
Title |
---|
BIOLOGICAL ABSTRACTS vol. 79, no. 8 , 1985, Philadelphia, PA, US; abstract no. 65685, F.R. VENEZIO ET AL. 'BACTERICIDAL EFFECTS OF PHOTORADIATION THERAPY WITH HEMATOPORPHYRIN DERIVATIVE.' page AB-169 ; * |
BIOLOGICAL ABSTRACTS vol. 82, no. 6 , 1986, Philadelphia, PA, US; abstract no. 57414, P. MARTINETTO ET AL. 'BACTERICIDAL EFFECTS INDUCED BY LASER IRRADIATION AND HEMATOPORPHYRIN AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE MICROORGANISMS.' page AB-856 ; * |
BIOLOGICAL ABSTRACTS vol. 90, no. 11 , 1990, Philadelphia, PA, US; abstract no. 119702, Z. MALIK ET AL. 'THE BACTERICIDAL ACTIVITY OF A DEUTEROPORPHYRIN-HEMIN MIXTURE ON GRAM-POSITIVE BACTERIA: A MICROBIOLOGICAL AND SPECTROSCOPIC STUDY.' page AB-175 ; * |
CHEMICAL ABSTRACTS, vol. 96, no. 19, 10 Mai 1982, Columbus, Ohio, US; abstract no. 159141, F.I. BUROVAYA ET AL. 'STUDY OF THE EFFECT OF CONDITIONS OF HYDROLYSIS OF AN ERYTHROCYTE MASS (BYPRODUCTS OF PRODUCTION) ON THE COMPOSITION OF HYDROLYZATES.' page 436 ; * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033463A2 (fr) * | 1994-06-02 | 1995-12-14 | Bar-Ilan University | Compositions antibiotiques synergique contenant une porphyrine et un antibiotique |
WO1995033463A3 (fr) * | 1994-06-02 | 1996-05-17 | Univ Bar Ilan | Compositions antibiotiques synergique contenant une porphyrine et un antibiotique |
EP0824213A2 (fr) * | 1996-08-15 | 1998-02-18 | Tsukasa Matsumoto | Méthode pour le fractionnement des globules rouges et matériaux antibactériens ou inhibiteurs de prolifération bactérienne ainsi produit |
EP0824213A3 (fr) * | 1996-08-15 | 1998-06-17 | Tsukasa Matsumoto | Méthode pour le fractionnement des globules rouges et matériaux antibactériens ou inhibiteurs de prolifération bactérienne ainsi produit |
Also Published As
Publication number | Publication date |
---|---|
JPH07501328A (ja) | 1995-02-09 |
ZA928679B (en) | 1993-05-11 |
CA2123587A1 (fr) | 1993-05-27 |
AU3163093A (en) | 1993-06-15 |
EP0613484A1 (fr) | 1994-09-07 |
FR2683724A1 (fr) | 1993-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8629181B2 (en) | Biologically active oils | |
US11241470B2 (en) | Phaseolus vulgaris extracts, their use and formulations containing them | |
WO2012004522A1 (fr) | Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe macromoleculaire pour prevenir et traiter les rhumatismes inflammatoires | |
EP2326708B1 (fr) | Microorqanismes photosynthétiques enrichis en sélénium à partir de composés séléno-hydroxyacides, leurs applications en nutrition, cosmétique et pharmacie | |
JP6741280B2 (ja) | Ace阻害、血圧上昇抑制、又は血圧降下に用いられる組成物、及びその製造方法 | |
WO1993010153A1 (fr) | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire | |
SU1732815A3 (ru) | Способ получени гипотриглицеридально-активных полисахаридов | |
CH620691A5 (fr) | ||
FR2481927A1 (fr) | Composition anti-allergique et son procede de preparation a partir d'une bacterie lactique du genre streptococcus | |
WO2020260356A1 (fr) | Bacterie de la famille des christensenellacees et composition en contenant pour la prevention et/ou le traitement de l'insuffisance renale | |
JPH07285881A (ja) | アルコール代謝促進剤 | |
FR2884829A1 (fr) | Procede d'obtention d'un extrait bacterien d'aeromonas hydrophila provenant de sangsues, et compositions pharmaceutiques les contenant | |
EP1194154B1 (fr) | Utilisation de bacteries propioniques pour la production d'acide propionique et/ou de propionates dans le colon | |
CA1122526A (fr) | Substance biologiquement active, sa preparation et les medicaments qui la contiennent | |
FR2536281A1 (fr) | Compositions pharmaceutiques permettant de reguler les fonctions phagocytaires | |
FR2834292A1 (fr) | Extraits bacteriens de sangsues a effet notamment thrombolytique | |
FR2640281A1 (fr) | Concentre enzymatique liquide stable et procede pour sa production | |
FR2655267A1 (fr) | Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant. | |
LU86418A1 (fr) | Polysaccharides azotes et leur procede d'obtention | |
BE566435A (fr) | ||
JPH0494682A (ja) | グルタチオンペルオキシダーゼの製造法およびその用途 | |
JPS5922517B2 (ja) | 抗腫瘍性多糖類c↓−45の製造法 | |
JPH03240495A (ja) | 新規生理活性物質サイクロオクタチン、その製造法およびその用途 | |
FR2796555A1 (fr) | Utilisation de bacteries propioniques pour la production d'acide propionique et/ou de propionates et, le cas echeant, d'acide acetique et/ou d'acetates au niveau du colon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CS FI HU JP KR NO PL RO RU UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993900252 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2123587 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1994 244065 Country of ref document: US Date of ref document: 19940516 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993900252 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993900252 Country of ref document: EP |